Craig Gedye
Craig Gedye
Conjoint Associate Professor, Hunter Medical Research Institute
Verified email at
Cited by
Cited by
An immune atlas of clear cell renal cell carcinoma
S Chevrier, JH Levine, VRT Zanotelli, K Silina, D Schulz, M Bacac, ...
Cell 169 (4), 736-749. e18, 2017
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
The Lancet 397 (10276), 797-804, 2021
Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide
Biochemical Journal 321 (2), 503-508, 1997
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells
JM Stewart, PA Shaw, C Gedye, MQ Bernardini, BG Neel, LE Ailles
Proceedings of the National Academy of Sciences 108 (16), 6468-6473, 2011
The regulatory T cell–associated transcription factor FoxP3 is expressed by tumor cells
LM Ebert, BS Tan, J Browning, S Svobodova, SE Russell, N Kirkpatrick, ...
Cancer research 68 (8), 3001-3009, 2008
Inhibition of myeloperoxidase by benzoic acid hydrazides
AJ Kettle, CA Gedye, MB Hampton, CC Winterbourn
Biochemical Journal 308 (2), 559-563, 1995
Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response …
L Emmett, M Crumbaker, B Ho, K Willowson, P Eu, L Ratnayake, ...
Clinical genitourinary cancer 17 (1), 15-22, 2019
Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the …
CN Sternberg, Y Loriot, N James, E Choy, D Castellano, F Lopez-Rios, ...
European urology 76 (1), 73-81, 2019
Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial
P Grimison, A Mersiades, A Kirby, N Lintzeris, R Morton, P Haber, I Olver, ...
Annals of Oncology 31 (11), 1553-1560, 2020
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP …
JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ...
The Lancet Oncology 23 (11), 1389-1397, 2022
Superoxide is an antagonist of anti-inflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase
AJ Kettle, CA Gedye, CC Winterbourn
Biochemical pharmacology 45 (10), 2003-2010, 1993
Infectious complications of biological and small molecule targeted immunomodulatory therapies
JS Davis, D Ferreira, E Paige, C Gedye, M Boyle
Clinical microbiology reviews 33 (3), 10.1128/cmr. 00035-19, 2020
TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic …
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
Lancet 397 (10276), 797-804, 2021
Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneity
CA Gedye, A Hussain, J Paterson, A Smrke, H Saini, D Sirskyj, K Pereira, ...
PloS one 9 (8), e105602, 2014
TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC …
MS Hofman, L Emmett, SK Sandhu, A Iravani, AM Joshua, JC Goh, ...
Journal of Clinical Oncology 38 (15_suppl), 5500-5500, 2020
Predicting clinical outcome through molecular profiling in stage III melanoma
T John, MA Black, TT Toro, D Leader, CA Gedye, ID Davis, PJ Guilford, ...
Clinical Cancer Research 14 (16), 5173-5180, 2008
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells
C Gedye, J Quirk, J Browning, S Svobodová, T John, P Sluka, PR Dunbar, ...
Cancer immunology, immunotherapy 58, 1635-1646, 2009
Human perforin mutations and susceptibility to multiple primary cancers
JA Trapani, KYT Thia, M Andrews, ID Davis, C Gedye, P Parente, ...
Oncoimmunology 2 (4), e24185, 2013
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
L Khoja, M Kibiro, UR Metser, C Gedye, D Hogg, MO Butler, EG Atenafu, ...
British Journal of Cancer 115 (10), 1186-1192, 2016
Targeting the TSH receptor in thyroid cancer
CW Rowe, JW Paul, C Gedye, JM Tolosa, C Bendinelli, S McGrath, ...
Endocrine-Related Cancer 24 (6), R191-R202, 2017
The system can't perform the operation now. Try again later.
Articles 1–20